The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver

THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01956825

Enrollment

Registered

2013-10-08

Start date

2014-01-31

Completion date

2014-04-30

Last updated

2013-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease

Keywords

non alcoholic fatty liver disease, LCARNITINE amino acid, magnesium, fat content

Brief summary

Detailed description

The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease. the study is an interventional one in which 60 patients who by definition have non alcoholic fatty licer disease (NAFLD) are divided randomly (double blind) into 2 groups: group 1: study group. receive a product (flavoured water) which contains L-CARNITINE an magnesium. group 2: control. receive placebo. regular water. Length of trial - 12 weeks. The patients will be followed on a weekly base and variuos parameters will be compared (weight, lipid profile, insulin resistance etc.). fibrotest will be used at the beginning of the trial and at the end (week 12) comparing the fat content before and after the treatment.

Interventions

DIETARY_SUPPLEMENTslim water

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

age\>18, \<80 y evidence to non alcoholic fatty liver disease

Exclusion criteria

age\<18, \>80 y pregnancy renal failure congestive heart failure active malignancy liver disease - etiology other than non alcoholic fatty liver disease (NAFLD). hypothyroidism/cushing total prenteral nutrition (TPN) in the last 6 month

Design outcomes

Primary

Measure	Time frame
effect of LCARNITINE and magnesium treatment on the liver fat content	12 weeks

Secondary

Measure	Time frame	Description
effect of L-CARNITINE and magnesium treatment on the metabolic panel	12 weeks	hepatic enzyme profile, lipid profile, weight, inflammatory markers, insulin resistance

Countries

Israel

Contacts

Primary ContactDAN FELDMAN, MD

danifel100@gmail.com0522794025

Backup ContactYONA KITAY, MD

yonaki@clalit.org.il09-7471560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026